Semalty Mona, Panchpuri Mitali, Singh Devendra, Semalty Ajay
Department of Pharmaceutical Sciences, H. N. B. Garhwal University, Srinagar (Garhwal) 246 174, Uttarakhand, India.
Curr Drug Discov Technol. 2014 Jun;11(2):154-61. doi: 10.2174/15701638113106660043.
Racecadotril is an antisecretory and antidiarrheal agent against watery diarrhoea in children. Racecadotril is a class II drug (as per Biopharmaceutical Classification System) with poor aqueous solubility and dissolution rate limited absorption. β-cyclodextrin complexation of solubility or dissolution rate limited drugs provides an amphiphilic complex with improved solubility and dissolution profile. Thus Racecadotril - β-cyclodextrin complex were prepared to improve its solubility and dissolution by imparting an environment of improved hydrophilicity. Racecadotril was complexed with β-cyclodextrin (in 1:1 and 1:2 molar ratios) by two different methods (solvent evaporation and kneading method). These inclusion complexes were evaluated for solubility, drug content, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X ray powder diffraction (XRPD) and in vitro dissolution study. The highest drug content (30.83%) was found in complex made by kneading method (RK1:1) in 1:1 molar ratio. Complex prepared by solvent evaporation method (RSE1:1, RSE1:2) were found to be showing irregular disc shaped non-porous surface, while the complexes prepared by kneading method (RK1:1, RK1:2) showed rough, fluffy, non-porous and irregular surface in SEM. Solubility of the drug improved up to 2 to 3 folds in the complexes. The complex RK1:1 showed the greatest improvement in solubility (from 28.98 to76.56 µg/ml). The dissolution of the complexes was also found to be improved. Complex prepared by solvent evaporation method in 1:1 molar ratio (RSE1:1) showed a marked improvement in percent drug release (100.33%) than that of pure drug (52.58%) at the end of 1 hour in dissolution study. FTIR, DSC and XRPD data confirmed the formation of inclusion complex. It was concluded that water solubility of all the complexes were increased when the drug was complexed with β-CD in 1:1 molar ratio. The complex made in 1:1 molar ratio (irrespective of the method) showed better solubility and the dissolution profile as compared to the complex made in 1:2 molar ratio. It was concluded that the complex prepared by the solvent evaporation method showed better solubility and the dissolution due to better amorphization of the drug.
消旋卡多曲是一种治疗儿童水样腹泻的抗分泌和止泻药物。消旋卡多曲是II类药物(根据生物药剂学分类系统),其水溶性差且溶出速率有限,吸收也受限。对溶解度或溶出速率受限的药物进行β-环糊精包合,可形成具有改善的溶解度和溶出特性的两亲性复合物。因此,制备了消旋卡多曲-β-环糊精复合物,通过营造改善的亲水性环境来提高其溶解度和溶出度。消旋卡多曲与β-环糊精以两种不同方法(溶剂蒸发法和捏合法)按1:1和1:2的摩尔比进行包合。对这些包合物进行了溶解度、药物含量、扫描电子显微镜(SEM)、差示扫描量热法(DSC)、X射线粉末衍射(XRPD)及体外溶出度研究。发现捏合法制备的1:1摩尔比的包合物(RK1:1)药物含量最高(30.83%)。溶剂蒸发法制备的包合物(RSE1:1、RSE1:2)在SEM中显示为不规则盘状无孔表面,而捏合法制备的包合物(RK1:1、RK1:2)在SEM中显示为粗糙、蓬松、无孔且不规则的表面。药物在包合物中的溶解度提高了2至3倍。RK1:1包合物的溶解度改善最大(从28.98提高到76.56 µg/ml)。还发现包合物的溶出度也有所提高。在溶出度研究中,溶剂蒸发法制备的1:1摩尔比的包合物(RSE1:1)在1小时结束时的药物释放百分比(100.33%)比纯药物(52.58%)有显著提高。FTIR、DSC和XRPD数据证实了包合物的形成。得出结论:当药物与β-CD按1:1摩尔比包合时,所有包合物的水溶性均增加。与1:2摩尔比制备的包合物相比,1:1摩尔比制备的包合物(无论采用何种方法)显示出更好的溶解度和溶出特性。得出结论:溶剂蒸发法制备的包合物由于药物更好的无定形化而显示出更好的溶解度和溶出度。